|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
N03AX11
|
|
gptkbp:cause
|
glaucoma
metabolic acidosis
hyperammonemia
kidney stones
oligohidrosis
|
|
gptkbp:contraindication
|
pregnancy
allergy to topiramate
|
|
gptkbp:drugClass
|
anticonvulsant
antiepileptic
|
|
gptkbp:eliminationHalfLife
|
21 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:tablet
capsule
|
|
gptkbp:genericName
|
gptkb:topiramate
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Topamax
|
|
gptkbp:interactsWith
|
gptkb:metformin
gptkb:beer
gptkb:phenytoin
gptkb:warfarin
gptkb:valproic_acid
gptkb:CNS_depressants
gptkb:carbamazepine
gptkb:amitriptyline
gptkb:pioglitazone
gptkb:risperidone
gptkb:hydrochlorothiazide
gptkb:digoxin
lithium
oral contraceptives
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
antagonizes AMPA/kainate glutamate receptors
blocks voltage-dependent sodium channels
enhances GABA activity
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyWarning
|
may cause birth defects
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
weight loss
cognitive impairment
drowsiness
paresthesia
|
|
gptkbp:usedFor
|
epilepsy
migraine prevention
|
|
gptkbp:bfsParent
|
gptkb:topiramate
|
|
gptkbp:bfsLayer
|
7
|